Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

Repligen stock has delivered a strong 45.1% one year return, yet the valuation signals are mixed, with the Discounted Cash Flow (DCF) estimate pointing to a price that is close to intrinsic value while market based multiples suggest the shares trade at a premium. That combination leaves Repligen looking less like an obvious bargain and more like a stock where the entry price matters. Repligen’s 45.1% return over the past year highlights that recent shareholders have been rewarded. This...

Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.

CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

In July 2026, Repligen Corporation reported second-quarter 2026 results showing revenue of US$204.13 million versus US$182.37 million a year earlier, while net income fell to US$5.01 million from US$14.87 million and diluted EPS from continuing operations decreased to US$0.09 from US$0.26. Over the six-month period ended June 30, 2026, Repligen grew revenue to US$398.38 million from US$351.54 million, but net income and EPS declined, highlighting pressure on profitability despite higher...

What Repligen’s Latest Earnings Mean For Shareholders Repligen (RGEN) is in focus after its second quarter 2026 earnings, which showed higher revenue alongside lower net income and earnings per share compared with the same period a year earlier. See our latest analysis for Repligen. Repligen’s recent earnings announcement and past share repurchase activity have come alongside strong momentum in the stock. The 90 day share price return of 41.4% and 1 year total shareholder return of 47.09%...

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.

TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.

Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.

The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported second-quarter results that beat analyst expectations and raised its full-year forecast.

Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy tools. The call represents new corporate activity that is separate from routine earnings updates. Repligen enters this M&A discussion with BioLife Solutions while its shares trade at $131.06. The stock is up 9.5% over the past year, although it is down 20.3% year to date and has declined 23.6%...

Repligen Corp (RGEN) reports robust revenue growth and increased full-year guidance, driven by significant gains in the Proteins segment and APAC region.

Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted

Repligen Corporation (NASDAQ:RGEN) reported double-digit second-quarter revenue growth and increased its full-year 2026 financial guidance, citing strong order momentum and continued market outperformance while highlighting its pending acquisition of BioLife Solutions. Key Investor TakeawaysRepligen raised its full-year 2026 guidance following stronger first-half performance and continued order momentum.

Repligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% year on year to $204.1 million. The company expects the full year’s revenue to be around $824 million, close to analysts’ estimates. Its non-GAAP profit of $0.54 per share was 20.4% above analysts’ consensus estimates.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday morning. Here’s what you need to know.

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th

Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing. Presi

The Dow Jones Industrial Average and the S&P 500 Index were up, while the Nasdaq Composite were down

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 7% in the morning session after investors reacted to the company's weak full-year guidance ahead of its upcoming earnings report, alongside concerns over project delays highlighted by industry peer Danaher. The cautious outlook amplified bearish sentiment before Repligen's second-quarter results, expected on July 28. The guidance signaled expectations for slower growth and tougher near-term conditions. Adding to th

Repligen stock is coming off a mixed five year stretch, with the share price lower over that window even as more recent returns have turned positive. The valuation signals now point to a stock that is not clearly cheap, with the Discounted Cash Flow (DCF) intrinsic value estimate sitting close to the current market price while traditional multiples lean expensive. Repligen shares are down 27.9% over five years, which puts the current valuation debate in the context of a long period where...

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.